Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[DTIC in malignant melanoma: a perspective (author's transl)].

E M Kokoschka

    Wiener Klinische Wochenschrift
    |December 22, 1978
    PubMed
    Summary

    Chemotherapy for malignant melanoma, like DTIC (dimethyl-triaceno-imidazol-carboxamide), has limited efficacy. Combining chemotherapy with immunotherapy shows promise for enhancing tumor elimination in melanoma treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer.

    Melanoma research·1999
    Same author

    [Thymopentin in alopecia areata].

    Acta medica Austriaca·1998
    Same author

    Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial.

    Archives of dermatology·1998
    Same author

    Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells.

    International journal of cancer·1997
    Same author

    Antitumor activity of imexon.

    Journal of the National Cancer Institute·1995
    Same author

    Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines.

    International journal of cancer·1994

    Area of Science:

    • Oncology
    • Immunology
    • Pharmacology

    Context:

    • Malignant melanoma presents therapeutic challenges.
    • Current chemotherapeutic agents, including DTIC (dimethyl-triaceno-imidazol-carboxamide), show limited objective response rates (up to 25%) in melanoma monotherapy.
    • Combination with other cytostatic agents has not improved DTIC efficacy.

    Purpose:

    • To review clinical studies on DTIC in malignant melanoma.
    • To explore the potential of combining chemotherapy with immunotherapy for melanoma treatment.

    Summary:

    • DTIC is a primary chemotherapeutic agent for melanoma, but its monotherapy effectiveness is restricted.
    • Combining DTIC chemotherapy with immunotherapy may enhance tumor elimination.
    • This review focuses on clinical data regarding DTIC in malignant melanoma.

    Impact:

    • Highlights the limitations of current melanoma chemotherapy.
    • Suggests a promising therapeutic strategy by combining chemotherapy with immunotherapy.
    • Provides a review of clinical evidence for DTIC in malignant melanoma treatment.

    Related Experiment Videos